



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/002,698	12/05/2001	Snezna Rogelj	UNME-0115-1	4017
7590 03/11/2004			EXAM	INER
COLEMAN SUDOL SAPONE, P.C.			LUKTON, DAVID	
	DLORADO AVE GEPORT, CT 06605-1601		ART UNIT	PAPER NUMBER
DRIDGEI OR I	, 01 00005-1001		1653	
			DATE MAILED: 03/11/200-	4

Please find below and/or attached an Office communication concerning this application or proceeding.

-		Application No.	Applicant(s)		
		10/002,698	ROGELJ ET AL.		
	Office Action Summary	Examiner	Art Unit		
		David Lukton	1653		
Period fo	- The MAILING DATE of this communication ap r Reply	pears on the cover sheet w	rith the correspondence address		
A SHO THE N - Exter after: - If the - If NO - Failur Any r	DRTENED STATUTORY PERIOD FOR REPL MAILING DATE OF THIS COMMUNICATION. Isions of time may be available under the provisions of 37 CFR 1.7 SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a rep period for reply is specified above, the maximum statutory period to to reply within the set or extended period for reply will, by statutely received by the Office later than three months after the mailined patent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, however, may a ly within the statutory minimum of thi will apply and will expire SIX (6) MO e. cause the application to become A	reply be timely filed rty (30) days will be considered timely. NTHS from the mailing date of this communication. IBANDONED (35 U.S.C. § 133).		
Status					
1)🖂	Responsive to communication(s) filed on 01 M	March 2004.			
2a)□	This action is FINAL . 2b)⊠ This action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the me					
	closed in accordance with the practice under	Ex parte Quayle, 1935 C.	D. 11, 453 O.G. 213.		
Dispositi	on of Claims				
4)⊠	Claim(s) 9-15 and 19-21 is/are pending in the	application.			
	4a) Of the above claim(s) is/are withdra				
5)	Claim(s) is/are allowed.				
6)□	Claim(s) is/are rejected.				
7)[Claim(s) is/are objected to.				
8)⊠	Claim(s) $\underline{9-15}$ and $\underline{19-21}$ are subject to restrict	tion and/or election requir	rement.		
Applicat	ion Papers				
	The specification is objected to by the Examin				
10)	The drawing(s) filed on is/are: a)☐ ac				
	Applicant may not request that any objection to the				
	Replacement drawing sheet(s) including the corre-				
11)	The oath or declaration is objected to by the E	Examiner. Note the attach	ed Office Action or form PTO-152.		
Priority (under 35 U.S.C. § 119				
12)	Acknowledgment is made of a claim for foreig	n priority under 35 U.S.C.	§ 119(a)-(d) or (f).		
	☐ All b)☐ Some * c)☐ None of:				
·	1. Certified copies of the priority documer	nts have been received.			
	2. Certified copies of the priority documer	nts have been received in			
	3. Copies of the certified copies of the pri				
	application from the International Bure				
* (See the attached detailed Office action for a lis	st of the certified copies no	ot received.		
Attachmer	nt(s)				
	ce of References Cited (PTO-892)		v Summary (PTO-413) o(s)/Mail Date		
	ce of Draftsperson's Patent Drawing Review (PTO-948) rmation Disclosure Statement(s) (PTO-1449 or PTO/SB/0		f Informal Patent Application (PTO-152)		
	er No(s)/Mail Date	6) 🔲 Other: _			

U.S. Patent and Trademark Office PTOL-326 (Rev. 1-04)

Pursuant to the preliminary amendment filed 12/5/01, claims 1-8, 16-18 have been cancelled, claims 9-15, 19 amended, and claims 20-21 added. Claims 9-15 and 19-21 are pending.

 \diamondsuit

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- 1. Claims 9-11, 20, drawn to compounds.
- 2. Claims 12 and 13, drawn to a method of inhibiting PDI.
- 3. Claims 14-15, drawn to a method of treating a viral infection.
- 4. Claims 19 and 21, drawn to a method for determining optimum blood concentration.

Inventions 1 and 2-4 are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP 806.05(h)). However, in the event that Group 1 is elected, and claims therein found allowable, the corresponding method-of-use claims will be rejoined for further examination.

Applicant is advised that for the response to this requirement to be complete, an election of the invention to be examined must be indicated, even if the requirement is traversed (37 C.F.R. 1.143).

Applicant is reminded that upon cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently filed petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(h).

In addition to the foregoing, applicants are required under 35 U.S.C. §121 to elect a disclosed specie for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. A "specie" is a specific compound, with variables R and R1 specifically described.

Applicant is advised that a response to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a generic claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are witten in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP 809.02(a).

Should applicant traverse on the ground that the species are not patentable distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. §103 of the other invention.

There appears to be a typographical error in claim 12, line 1. Perhaps the word "compounds" should be *comprising*.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Lukton whose telephone number is 571-272-0952. The examiner can normally be reached Monday-Friday from 9:30 to 6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low, can be reached at 571-272-0951.

The fax number for the organization where this application or proceeding is assigned is 703-872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 571-272-1600.

PATENT EXAMINER
GROUP 1822